Annual report
4536.TEDINET S100OEK1
Period2021-04-01 → 2022-03-31
Filed2022-06-24
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥266.3bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥249.6bn | 2020-04-01 → 2021-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥241.6bn | 2019-04-01 → 2020-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥234.0bn | 2018-04-01 → 2019-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥224.9bn | 2017-04-01 → 2018-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥35.9bn | 2021-04-01 → 2022-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥12.2bn | 2020-04-01 → 2021-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥35.6bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥11.7bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥32.1bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥43.1bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥39.3bn | 2017-04-01 → 2018-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥27.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥9.3bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥23.6bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥32.0bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥35.2bn | 2017-04-01 → 2018-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥27.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥9.1bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥460.0bn | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥405.3bn | at 2021-03-31 | Cons. | Assets IFRS |
| Total assets | ¥408.8bn | at 2020-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥391.2bn | at 2019-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥388.5bn | at 2018-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥123.1bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥95.6bn | at 2021-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥336.8bn | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥309.6bn | at 2021-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥302.6bn | at 2020-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥337.5bn | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥310.2bn | at 2021-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥302.9bn | at 2020-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥290.9bn | at 2019-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥285.8bn | at 2018-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥83.0bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥62.9bn | at 2021-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥91.4bn | at 2020-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥70.8bn | at 2019-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥69.3bn | at 2018-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥46.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥38.8bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥39.9bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥32.9bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥42.8bn | 2017-04-01 → 2018-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥35.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥53.4bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥5.2bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥2.9bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥8.3bn | 2017-04-01 → 2018-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | ¥5.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥16.7bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥12.7bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥28.1bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥17.6bn | 2017-04-01 → 2018-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥68.07 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥23.3 | 2020-04-01 → 2021-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥59.16 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥78.67 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥86.73 | 2017-04-01 → 2018-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥67.97 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥23.26 | 2020-04-01 → 2021-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥59.01 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥78.43 | 2018-04-01 → 2019-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥86.42 | 2017-04-01 → 2018-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥843.6 | at 2022-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥776.16 | at 2021-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥758.5 | at 2020-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥728.97 | at 2019-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥702.54 | at 2018-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 73.4% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 76.5% | at 2021-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 74.1% | at 2020-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 74.4% | at 2019-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 73.6% | at 2018-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 8.4% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 3.0% | 2020-04-01 → 2021-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 8.0% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 11.1% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 13.0% | 2017-04-01 → 2018-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 4,315 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 4,229 | at 2021-03-31 | Cons. | Number of employees |
| Employees | 4,108 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 4,073 | at 2019-03-31d | Cons. | Number of employees |
| Employees | 3,805 | at 2018-03-31d | Cons. | Number of employees |
| Revenue | ¥190.8bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥186.1bn | 2020-04-01 → 2021-03-31 | Standalone | Net sales |
| Revenue | ¥182.6bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥176.2bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥171.9bn | 2017-04-01 → 2018-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥21.4bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Operating income | ¥23.6bn | 2020-04-01 → 2021-03-31 | Standalone | Operating income |
| Ordinary income | ¥22.5bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥25.3bn | 2020-04-01 → 2021-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥34.9bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥33.2bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥31.7bn | 2017-04-01 → 2018-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥25.2bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥27.4bn | 2020-04-01 → 2021-03-31 | Standalone | Income before income taxes |
| Net income | ¥17.4bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥21.8bn | 2020-04-01 → 2021-03-31 | Standalone | Profit loss |
| Net income | ¥27.4bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥28.0bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥25.4bn | 2017-04-01 → 2018-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥363.8bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥353.6bn | at 2021-03-31 | Standalone | Assets |
| Total assets | ¥340.0bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥321.9bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥320.8bn | at 2018-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥66.3bn | at 2022-03-31 | Standalone | Liabilities |
| Total liabilities | ¥59.4bn | at 2021-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥297.5bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥294.2bn | at 2021-03-31 | Standalone | Net assets |
| Net assets / equity | ¥283.5bn | at 2020-03-31d | Standalone | Net assets |
| Net assets / equity | ¥265.4bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥265.8bn | at 2018-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥37.6bn | at 2022-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥24.7bn | at 2021-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥43.59 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥54.44 | 2020-04-01 → 2021-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥68.63 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥68.96 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥62.58 | 2017-04-01 → 2018-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥43.53 | 2021-04-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥54.33 | 2020-04-01 → 2021-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥68.46 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥68.76 | 2018-04-01 → 2019-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥62.36 | 2017-04-01 → 2018-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥32 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2020-04-01 → 2021-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥27 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥26 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥26 | 2017-04-01 → 2018-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥742.3 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥734.61 | at 2021-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥708.12 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥662.95 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥650.84 | at 2018-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 81.7% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.1% | at 2021-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.2% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 82.2% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 82.5% | at 2018-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 5.9% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.5% | 2020-04-01 → 2021-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.0% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.6% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.0% | 2017-04-01 → 2018-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 400,695,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 400,369,000 | at 2021-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 400,028,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 399,782,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 406,848,000 | at 2018-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 1,839 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 1,872 | at 2021-03-31 | Standalone | Number of employees |
| Employees | 1,840 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 1,812 | at 2019-03-31d | Standalone | Number of employees |
| Employees | 1,859 | at 2018-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
All source rows · 1,628
| Item | Context | Value | Unit |
|---|---|---|---|
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row3Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row4Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row5Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row6Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row7Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row8Member | Text · Plus | |
| Outside directors and outside corporate auditors (text) | FilingDateInstant | Text · Plus | |
| Audits (text) | FilingDateInstant | Text · Plus | |
| Remuneration for directors and other officers (text) | FilingDateInstant | Text · Plus | |
| Remuneration etc paid by group to each director or other officer (text) | FilingDateInstant | Text · Plus | |
| Shareholdings (text) | FilingDateInstant | Text · Plus | |
| Reason for increase in number of shares shares not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | － | |
| Reason for increase in number of shares shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | － | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)小野薬品工業株式会社 | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)眼科領域における事業関係の強化及び企業価値の向上（注） | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Original text (Japanese)エーザイ株式会社 | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Original text (Japanese)眼科領域における事業関係の強化及び企業価値の向上（注） | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Original text (Japanese)株式会社メディパルホールディングス | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Original text (Japanese)眼科領域における事業関係の強化及び企業価値の向上（注） | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row4Member | Original text (Japanese)生化学工業株式会社 | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row4Member | Original text (Japanese)眼科領域における事業関係の強化及び企業価値の向上（注） | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row4Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Original text (Japanese)株式会社三菱UFJフィナンシャル・グループ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Original text (Japanese)財務活動における取引関係の強化及び企業価値の向上（注） | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row6Member | Original text (Japanese)株式会社QDレーザ | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row6Member | Original text (Japanese)眼科領域における事業関係の強化及び企業価値の向上（注） | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row6Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row7Member | Original text (Japanese)東邦ホールディングス株式会社 | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row7Member | Original text (Japanese)眼科領域における事業関係の強化及び企業価値の向上（注） | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row7Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row8Member | Original text (Japanese)株式会社スズケン | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row8Member | Original text (Japanese)眼科領域における事業関係の強化及び企業価値の向上（注） | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row8Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row9Member | Original text (Japanese)株式会社バイタルケーエスケー・ホールディングス | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row9Member | Original text (Japanese)眼科領域における事業関係の強化及び企業価値の向上（注） | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row9Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row10Member | Original text (Japanese)大木ヘルスケアホールディングス株式会社 | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row10Member | Original text (Japanese)眼科領域における事業関係の強化及び企業価値の向上（注） | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row10Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row11Member | Original text (Japanese)株式会社ほくやく・竹山ホールディングス | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row11Member | Original text (Japanese)眼科領域における事業関係の強化及び企業価値の向上（注） | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row11Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row12Member | Original text (Japanese)富士フイルムホールディングス株式会社 | |
| Purpose of shareholding quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row12Member | Original text (Japanese)眼科領域における事業関係の強化及び企業価値の向上のため株式を保有していましたが、当事業年度において全株式を売却しました。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row12Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row13Member | Original text (Japanese)小林製薬株式会社 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |